Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of RO6836191 in healthy male volunteers
NL-OMON40173Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of baxdrostat in cardiac morbidity and hypertension (HTN) (2 arms), sponsored by Roche. Primary endpoints: Safety and tolerability, Pharmacokinetics of oral dosing and 1 more. Started Oct 2013; status: active, not recruiting.
02
Drugs
baxdrostat
03
Conditions
cardiac morbidityhypertension (HTN)
Beyond the preview
Go deeper on NL-OMON40173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40173.